Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingSRPT
Biotech & Genomic Medicine▼2
Sarepta's Q2 Earnings and Sales Beat Estimates, 2026 Outlook Updated
Sarepta Therapeutics reported second-quarter 2026 adjusted earnings per share of 64 cents, beating the Zacks Consensus Estimate of 58 cents but falling 68% year over year. Total revenues were $401.3 million, down 34% from a year ago, yet exceeded the consensus estimate of $355.6 million. Product revenues declined 36% to $328.7 million, with Elevidys sales dropping 65% to $98.1 million due to a shipment suspension for non-ambulatory patients, while PMO product revenues were relatively flat at $230.6 million. The company narrowed its 2026 net product revenue guidance to $1.2-$1.3 billion from the prior $1.2-$1.4 billion range and raised its collaboration and other revenues forecast to $550-$600 million, primarily on higher expected contract manufacturing revenues. Sarepta also tightened its combined adjusted R&D and SG&A expense guidance to $800-$850 million from $800-$900 million.
Sarepta Therapeutics grants equity awards to new CEO Michael Severino
Sarepta Therapeutics granted equity awards to Michael Severino, M.D. as a material inducement to his employment as Chief Executive Officer. The awards, approved under the company's 2024 Employment Commencement Incentive Plan, consist of options to purchase 2,224,342 shares of common stock and 756,104 restricted stock units. The options have an exercise price of $17.74 per share, a 15% premium to the July 28, 2026 closing price, and vest over four years with one-fourth vesting after one year and the remainder monthly thereafter. The restricted stock units vest in equal annual installments over four years, subject to continued employment.
Sarepta Therapeutics names Michael Severino as chief executive officer
Sarepta Therapeutics has appointed Michael Severino, M.D., as its new chief executive officer, effective July 28, 2026. Severino, who previously served as CEO of Tessera Therapeutics and held senior roles at AbbVie and Amgen, will also join Sarepta's Board of Directors. He succeeds Doug Ingram, who is retiring and will remain in an advisory capacity until the end of 2026. The company highlighted Severino's more than 25 years of biopharmaceutical experience and his track record of contributing to over a dozen approved therapies.
Sarepta Therapeutics Stock in Focus After FDA Accepts sNDA for Duchenne Drugs
Sarepta Therapeutics announced that the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, seeking conversion from accelerated to traditional approvals in Duchenne muscular dystrophy. The regulatory step is backed by Phase 3 ESSENCE data and real-world evidence on efficacy trends and safety. Sarepta's share price recently gained 22.93% over one month to $18.82, though it remains down 15.03% over 90 days and 82.46% over three years. Analysts have a consensus price target of $21.65, implying the stock is undervalued, but the company faces risks including renewed scrutiny of ELEVIDYS safety and potential weaker-than-expected uptake of its gene therapy portfolio.
Recursion Pharmaceuticals and Sarepta Therapeutics remain unattractive despite price drops
Recursion Pharmaceuticals and Sarepta Therapeutics have underperformed this year and still do not merit investment, according to an analysis. Recursion Pharmaceuticals, an AI-driven drugmaker founded in 2013, has no products on the market and none in late-stage studies, while facing growing competition in AI drug discovery. Sarepta Therapeutics saw two patient deaths last year linked to its Elevidys therapy for Duchenne muscular dystrophy, leading to a restricted label and a boxed warning for liver injury; the company is testing an immunosuppressant to mitigate risks, but Elevidys remains central to its prospects and vulnerable to new competitors. Both stocks carry significant clinical and regulatory risks that make them unattractive for most long-term investors.
Sarepta Therapeutics Grants Inducement Equity Awards to 30 New Hires
Sarepta Therapeutics granted equity awards to 30 individuals hired in the second quarter of 2026 as a material inducement to employment. The awards, approved under the company's 2024 Employment Commencement Incentive Plan, consist of an aggregate of 151,305 restricted stock units. One-fourth of the RSUs will vest yearly on each anniversary of the grant date, with full vesting on the fourth anniversary, subject to continued employment. No stock options were granted.
FDA accepts Sarepta's sNDAs for AMONDYS 45 and VYONDYS 53 with February 2027 target action date
Sarepta Therapeutics announced that the U.S. Food and Drug Administration has accepted for review the supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53 for the treatment of Duchenne muscular dystrophy. The FDA assigned a target action date of February 28, 2027 under the Prescription Drug User Fee Act. The submissions seek to convert the accelerated approvals of both exon-skipping therapies to traditional approvals, supported by data from the ESSENCE confirmatory study and published real-world evidence. Sarepta's president of research and development, Louise Rodino‑Klapac, said the acceptance is an important step for the Duchenne community, noting that more than 1,800 people worldwide have been treated across the company's exon-skipping portfolio. The ESSENCE study's primary endpoint was not met, but numerical trends favored treatment, and additional analyses showed increased dystrophin expression and consistent reduction in functional decline at week 96.